CD274 and cancer: Inhibiting FASN not only reduces cell growth in various cancer models, including leukemia, but also lowers PD-L1 expression on tumor cells [173], offering a therapeutic avenue to reprogram T-cell metabolism and potentially shield them from tumor-induced immunosuppression.